表皮生长因子受体酪氨酸激酶抑制剂耐药性疾病。
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
机构信息
University School of Medicine, Nashville,TN, USA.
出版信息
J Clin Oncol. 2013 Mar 10;31(8):1070-80. doi: 10.1200/JCO.2012.43.3912. Epub 2013 Feb 11.
Abstract
PURPOSE
EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease.
METHODS
This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.
RESULTS
The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.
CONCLUSION
The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.
摘要
目的
EGFR 突变型肺癌于 2004 年首次被描述为一种新的临床实体。在这里，我们对该疾病的新争议和结论进行了更新。
方法
本文回顾了肺癌中 EGFR 突变的临床意义，重点关注表皮生长因子受体酪氨酸激酶抑制剂耐药性。
结果
EGFR 突变的发现改变了我们对非小细胞肺癌（NSCLC）的考虑和治疗方式。转移性肿瘤携带 EGFR 突变的患者预期寿命超过 2 年，比肺癌的先前生存率提高了一倍以上。
结论
本综述中提供的信息可以指导临床医生，并帮助他们向患者告知 EGFR 突变及其对 NSCLC 治疗的影响。现在应集中精力使 EGFR 突变型肺癌成为一种慢性而非致命疾病。
相似文献
1
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.表皮生长因子受体酪氨酸激酶抑制剂耐药性疾病。
J Clin Oncol. 2013 Mar 10;31(8):1070-80. doi: 10.1200/JCO.2012.43.3912. Epub 2013 Feb 11.
2
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
3
Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.表皮生长因子受体-酪氨酸激酶抑制剂治疗失败后非小细胞肺癌患者的再次活检
Cancer Sci. 2016 Jul;107(7):1001-5. doi: 10.1111/cas.12963. Epub 2016 Jun 21.
4
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
5
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.克隆性 MET 扩增作为表皮生长因子受体突变型非小细胞肺癌酪氨酸激酶抑制剂耐药的决定因素。
J Clin Oncol. 2019 Apr 10;37(11):876-884. doi: 10.1200/JCO.18.00177. Epub 2019 Jan 24.
6
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.表皮生长因子受体突变的相对丰度可预测吉非替尼治疗晚期非小细胞肺癌的疗效。
J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25.
7
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).表皮生长因子受体（EGFR）突变在一系列非小细胞肺癌（NSCLC）患者中的存在情况，以及对 EGFR 特异性酪氨酸激酶抑制剂（TKIs）的反应率。
Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.
8
[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].[表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌中的临床研究与药物审评]
Zhonghua Zhong Liu Za Zhi. 2019 Dec 23;41(12):949-952. doi: 10.3760/cma.j.issn.0253-3766.2019.12.012.
9
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.临床因素预测 EGFR 突变型非小细胞肺癌再次活检中 T790M 突变的检测。
Clin Lung Cancer. 2018 Mar;19(2):e247-e252. doi: 10.1016/j.cllc.2017.07.002. Epub 2017 Aug 10.
10
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）治疗携带 TKI 敏感型 EGFR 突变的非小细胞肺癌患者的原发耐药：一项探索性研究。
Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.
引用本文的文献
1
Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌时发生间质性肺疾病的风险：一项真实世界药物警戒研究
Front Pharmacol. 2025 Aug 29;16:1652750. doi: 10.3389/fphar.2025.1652750. eCollection 2025.
2
TRPML3‑mediated lysosomal Ca release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non‑small cell lung cancer.瞬时受体电位黏蛋白3（TRPML3）介导的溶酶体钙释放增强药物隔离和生物合成，促进非小细胞肺癌对奥希替尼的耐药性。
Oncol Rep. 2025 Sep;54(3). doi: 10.3892/or.2025.8946. Epub 2025 Jul 19.
3
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC.CD47的RNA甲基化介导EGFR-TKI耐药非小细胞肺癌中的肿瘤免疫抑制。
Br J Cancer. 2025 Apr;132(6):569-579. doi: 10.1038/s41416-025-02945-2. Epub 2025 Feb 3.
4
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC.这可能是一条死胡同：表皮生长因子受体（EGFR）突变的非小细胞肺癌中的免疫检查点抑制剂疗法。
Explor Target Antitumor Ther. 2024;5(4):826-840. doi: 10.37349/etat.2024.00251. Epub 2024 Jul 19.
5
MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma.微小 RNA 作为胶质母细胞瘤替莫唑胺耐药的关键调节因子。
Mol Brain. 2024 Jul 2;17(1):42. doi: 10.1186/s13041-024-01113-6.
6
Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics.PD-L1 翻译后修饰的调控及新型小分子治疗药物的相关机会。
Future Med Chem. 2024 Aug 2;16(15):1583-1599. doi: 10.1080/17568919.2024.2366146. Epub 2024 Jul 1.
7
EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.EHMT2 介导的转录重编程驱动非小细胞肺癌中的神经内分泌转化。
Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2317790121. doi: 10.1073/pnas.2317790121. Epub 2024 May 30.
8
Droplet Digital PCR as a Molecular Tool for the Detection of the T790M Mutation in NSCLC Patients with the Activating Mutations.液滴数字PCR作为检测具有激活突变的非小细胞肺癌患者T790M突变的分子工具
Balkan J Med Genet. 2024 Mar 12;26(2):21-26. doi: 10.2478/bjmg-2023-0020. eCollection 2023 Dec.
9
Rare case report: a case of histological type transformation of lung cancer caused by neoadjuvant immunotherapy.罕见病例报告：1例新辅助免疫治疗导致肺癌组织学类型转化的病例
Front Oncol. 2024 Feb 15;14:1329152. doi: 10.3389/fonc.2024.1329152. eCollection 2024.
10
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.接受免疫检查点抑制剂治疗的 EGFR 突变型非小细胞肺癌患者的临床特征：CS-Lung-003 前瞻性观察性注册研究。
J Cancer Res Clin Oncol. 2024 Feb 12;150(2):89. doi: 10.1007/s00432-024-05618-4.
本文引用的文献
1
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的非小细胞肺癌患者的再次活检：T790M 突变阳性和突变阴性人群的比较。
Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.
2
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的晚期非小细胞肺癌中厄洛替尼化疗或单纯化疗。
Oncologist. 2013;18(11):1214-20. doi: 10.1634/theoncologist.2013-0168. Epub 2013 Sep 26.
3
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.表皮生长因子受体酪氨酸激酶抑制剂治疗在厄洛替尼治疗晚期非小细胞肺癌长期高加索反应者中的进展后：一项总生存的病例对照研究。
Lung Cancer. 2013 Jun;80(3):306-12. doi: 10.1016/j.lungcan.2013.02.010. Epub 2013 Mar 11.
4
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.ERK 信号的再激活导致对 EGFR 激酶抑制剂的耐药性。
Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7.
5
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.HER2 扩增：一种可能的机制，解释了 EGFR 突变型肺癌在缺乏第二部位 EGFRT790M 突变的情况下对 EGFR 抑制产生获得性耐药的原因。
Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5.
6
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.具有获得性 EGFR 抑制剂耐药的肺癌偶尔会发生 BRAF 基因突变，但缺乏 KRAS、NRAS 或 MEK1 突变。
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.
7
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.AXL 激酶的激活导致肺癌对 EGFR 靶向治疗产生耐药性。
Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.
8
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
9
Screening for germline EGFR T790M mutations through lung cancer genotyping.通过肺癌基因分型进行胚系 EGFR T790M 突变筛查。
J Thorac Oncol. 2012 Jun;7(6):1049-52. doi: 10.1097/JTO.0b013e318250ed9d.
10
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.CRKL 扩增诱导人类非小细胞肺癌的转化和表皮生长因子受体抑制剂耐药性。
Cancer Discov. 2011 Dec;1(7):608-25. doi: 10.1158/2159-8290.CD-11-0046. Epub 2011 Oct 17.
Zotero 插件